Onsdag 4 December | 13:18:55 Europe / Stockholm

Kalender

Tid*
2024-08-29 - Kvartalsrapport 2024-Q2
2024-06-19 - Årsstämma
2024-06-06 - X-dag ordinarie utdelning CRNA 0.00 NOK
2024-04-25 - Bokslutskommuniké 2023
2023-10-04 - Split CRNA 30:1
2023-08-24 - Kvartalsrapport 2023-Q2
2023-05-22 - Årsstämma
2023-04-21 - X-dag ordinarie utdelning CRNA 0.00 NOK
2023-03-09 - Extra Bolagsstämma 2023
2023-02-16 - Bokslutskommuniké 2022
2022-11-03 - Kvartalsrapport 2022-Q3
2022-08-18 - Kvartalsrapport 2022-Q2
2022-05-12 - Kvartalsrapport 2022-Q1
2022-04-20 - Årsstämma
2022-04-07 - X-dag ordinarie utdelning CRNA 0.00 NOK
2022-02-17 - Bokslutskommuniké 2021
2021-11-25 - Extra Bolagsstämma 2021
2021-11-04 - Kvartalsrapport 2021-Q3
2021-08-18 - Kvartalsrapport 2021-Q2
2021-05-06 - Kvartalsrapport 2021-Q1
2021-03-18 - X-dag ordinarie utdelning CRNA 0.00 NOK
2021-03-17 - Årsstämma
2021-02-18 - Bokslutskommuniké 2020
2020-11-05 - Kvartalsrapport 2020-Q3
2020-08-20 - Kvartalsrapport 2020-Q2
2020-05-07 - Kvartalsrapport 2020-Q1
2020-04-30 - X-dag ordinarie utdelning CRNA 0.00 NOK
2020-04-29 - Årsstämma
2020-03-11 - Bokslutskommuniké 2019
2019-11-07 - Kvartalsrapport 2019-Q3
2019-08-22 - Kvartalsrapport 2019-Q2
2019-05-09 - Kvartalsrapport 2019-Q1
2019-04-10 - X-dag ordinarie utdelning CRNA 0.00 NOK
2019-04-09 - Årsstämma
2019-02-14 - Bokslutskommuniké 2018
2018-11-01 - Kvartalsrapport 2018-Q3
2018-08-23 - Kvartalsrapport 2018-Q2
2018-05-03 - Kvartalsrapport 2018-Q1
2018-04-12 - X-dag ordinarie utdelning CRNA 0.00 NOK
2018-04-11 - Årsstämma
2018-02-15 - Bokslutskommuniké 2017
2017-11-16 - Kvartalsrapport 2017-Q3
2017-08-24 - Kvartalsrapport 2017-Q2
2017-04-25 - Kvartalsrapport 2017-Q1
2017-04-05 - Årsstämma
2017-02-16 - Bokslutskommuniké 2016
2016-11-17 - Kvartalsrapport 2016-Q3
2016-08-25 - Kvartalsrapport 2016-Q2
2016-05-12 - Kvartalsrapport 2016-Q1
2016-04-14 - X-dag ordinarie utdelning CRNA 0.00 NOK
2016-04-13 - Årsstämma
2015-06-23 - X-dag ordinarie utdelning CRNA 0.00 NOK
2015-06-22 - Årsstämma

Beskrivning

LandNorge
ListaOB Match
SektorHälsovård
IndustriBioteknik
Circio Holding är ett läkemedelsbolag. Bolaget specialistkompetens återfinns inom riktad immunterapi som används vid behandling av cancerpatienter. Bolagets verksamhet består av forskning och utveckling och läkemedlen säljs idag under separata varumärken. Ett flertal partnerskap på marknaden har ingåtts för att stärka samarbetet inom utvecklingen av ny immunterapi. Bolaget grundades 2010 och har sitt huvudkontor i Lysaker.
2021-08-09 07:00:10
Oslo, Norway, 9 August 2021 - Targovax ASA (OSE: TRVX) will announce its second
quarter and first half 2021 results on Wednesday 18 August 2021. An online
presentation by Targovax's management to investors, analysts and the press will
take place at 10:00 am CET.

The results report and the presentation will be available at
www.targovax.com (https://www.targovax.com/en/financial-reports/) in the
Investors section from 07:00 am CET.

Presentation

As a consequence of the Corona situation, there will only be a virtual
presentation of the results with a live webcast 18 August at 10.00 am CET. You
can join the webcast
here (https://channel.royalcast.com/landingpage/hegnarmedia/20210818_9/). It
will be possible to ask questions during the presentation.

For further information, please contact:
Oystein Soug, CEO
Phone: +47 906 56 525
Email: oystein.soug@targovax.com

Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com

Media enquires:
Andreas Tinglum - Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no

About Targovax

Activating the patient's immune system to fight cancer
Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing
immune activators to target hard-to-treat solid tumors. Targovax aims to unlock
greater clinical benefits in cancer patients by deploying multifunctional
platforms to target key immune regulators and oncogenic drivers. Targovax's
focus is to "activate the patient's immune system to fight cancer", thus
extending and transforming the lives of cancer patients. Targovax's pipeline
aims at different cancer indications, including melanoma, mesothelioma and
colorectal cancer. The products are designed to harness the patient's own immune
system to fight the cancer, whilst also delivering a favorable safety and
tolerability profile.

Targovax's lead clinical candidate, ONCOS-102, is a genetically modified
oncolytic adenovirus, which has been engineered to selectively infect cancer
cells and activate the immune system to fight the cancer. On the back of very
encouraging data in several indications, in monotherapy and in multiple
combination, the next development steps for ONCOS-102 will involve a clinical
trial with registration intent in checkpoint inhibitor refractory melanoma.